The Latest Cardiac and Vascular News
UTRECHT, The Netherlands, January 16, 2024–(BUSINESS WIRE)–AM-Pharma B.V. today announced that the first patients have been treated in a Phase 2 clinical study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as a preventive treatment for cardiac surgery-associated renal damage (CSA-RD). With over 2 million open heart surgeries1 performed worldwide every year, CSA-RD […]
OXFORD, England, Jan. 10, 2024 /PRNewswire/ — Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with Pfizer to support the validation and FDA clearance of its AI-based technology for the…
DENVER–(BUSINESS WIRE)–Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, today announced the launch of Cleerly ISCHEMIA, which recently received U.S. Food and Drug Administration (FDA) 510(k) medical device clearance. Cleerly ISCHEMIA analysis software is an automated machine learning-based decision support tool, intended […]
WALTHAM, Mass.–(BUSINESS WIRE)–Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication of new groundbreaking data reflecting the clinical impact of its flagship advanced preservation device, the Paragonix SherpaPak Cardiac Transport System (CTS), to protect and monitor donor hearts from extended criteria donors. In organ transplantation, an extended criteria donor is defined as having perceived risk factors linked to poor subsequent outcomes, for
Company’s award winning SSi Mantra surgical robotic system has completed over 550 surgeries and is clinically validated to perform more than 40 different types of surgical procedures Company Builds Strong Foundation for Future Growth FORT LAUDERDALE, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or […]
AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months AT-001 treatment resulted in a statistically significant difference in cardiac functional capacity in a prespecified subgroup of patients not receiving concomitant treatment with an SGLT2 or GLP-1 (p=0.040) and prevented clinically […]
CHICAGO–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions. “This isn’t just about predicting business risks that arise from workforce health outcomes; it’s about preventing them with actionable insights that help inform risk-reduction strategies to help employers reduce healthcare costs, bolster employee retention, and ultimately, […]
G3 is trailblazing the next frontier of cardiovascular disease SAN FRANCISCO, Jan. 4, 2024 /PRNewswire/ — G3 Therapeutics (“G3”), a global leader in the use of multiomic biological Big Data, has initiated a groundbreaking initiative to unravel the contribution of Lipoprotein(a) [“Lp(a)”]…
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has surpassed 250,000 patients receiving a HeartFlow FFRCT Analysis. This accomplishment is a testament to HeartFlow’s dedication to driving a new standard of care […]
MINNEAPOLIS, Jan. 3, 2024 /PRNewswire/ — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of enrollment in both their STIM-ADHF and STOP-ADHF pilot studies. Both studies were designed to evaluate the safety and performance of the Cardiac…
